Articles From: FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia to MarketAxess Reports Second Quarter 2014 Record Revenues of $65.0 Million, Pre-Tax Income of $29.1 Million and Diluted EPS of $0.48


Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced that the U.
Sign-up for FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0958816001&sourceType=1 http://www.ccnmatthews.com/logos/20110608-altus200.jpg TORONTO, ONTARIO --
Sign-up for Altus Group Strengthens its Data and Market Research Offering Through Acquisition of RealNet investment picks
2014/7/23
INDIANAPOLIS , July 23, 2014 /PRNewswire/ -- Simon, a leading global retail real estate company, today reported results for the quarter and six months ended June 30, 2014 .
Sign-up for Simon Property Group Reports Second Quarter 2014 Results And Raises Full Year 2014 Guidance investment picks
2014/7/23
-- Core(1) EPS $1.32 and reported EPS $1.29 --
Sign-up for PepsiCo Reports Second Quarter 2014 Results and Raises Full-Year EPS Guidance investment picks
District Court Judge Orders Apotex to Immediately Recall the Authorized Generic from its Direct Customers and to Stop Selling and Supplying the Product PITTSBURGH , July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil ® CR.
Sign-up for Mylan Wins Motion for Temporary Restraining Order Against Apotex for Authorized Generic of Paxil® CR investment picks
Janus Capital Group Inc. (“JCG”) (NYSE: JNS) today reported second quarter net income of $36.3 million, or $0.19 per diluted share, compared with first quarter 2014 net income of $30.5 million, or $0.16 per diluted share, and net income of $15.8 million, or $0.08 per diluted share, in the second quarter 2013.
Sign-up for Janus Capital Group Inc. Announces Second Quarter 2014 Results investment picks
2014/7/23
Horizonte announces filing in Canada of financial statements Canada NewsWire TORONTO , July 23, 2014 /CNW/ - Horizonte Minerals Plc (TSX:HZM, AIM:HZM) (the " Corporation ") announces that it has today filed in Canada its audited annual consolidated financial statements for the year ended December 31, 2013 , and its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2014 prepared in accordance with Canadian reporting requirements.
Sign-up for Horizonte announces filing in Canada of financial statements investment picks
Enphase Energy, Inc. (NASDAQ: ENPH) announced today that Australian Sustainable Energy Services (ASES) has installed an Enphase ® System at Hartley’s Crocodile Adventures , an eco-adventure attraction featuring Australia’s enchanting wildlife.
Sign-up for Enphase Energy Helps Hartley’s Crocodile Adventures Take A Bite Out of Electrical Bill investment picks
Joseph Corasanti Steps Down as CEO UTICA, N.Y., July 23, 2014 (GLOBE NEWSWIRE) -- CONMED Corporation (Nasdaq:CNMD) today announced that Joseph Corasanti is stepping down as Chief Executive Officer, President and a member of the Board of Directors, effective immediately.
Sign-up for CONMED Corporation Announces Leadership Transition investment picks
WAKE FOREST, N.C. , July 23, 2014 /PRNewswire/ -- PowerSecure International, Inc. (NYSE: POWR) today announced it has been awarded approximately $140 million of new distributed generation (DG) business.
Sign-up for PowerSecure Adds $140 Million In New Distributed Generation Business investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0958808001&sourceType=1 http://media3.marketwire.com/logos/20140303-GXIlogoLG.png TORONTO, ONTARIO --
Sign-up for GuestLogix to Announce Fiscal 2014 Second Quarter Results on August 11, 2014 investment picks
2014/7/23
- Diluted EPS from continuing operations rises 3.9 percent over second-quarter 2013 - Company-wide operating margins increase to 12.7 percent - Total backlog rises to $71.1 billion, 27 percent over first-quarter 2014 FALLS CHURCH, Va.
Sign-up for General Dynamics Reports Second-Quarter 2014 Results investment picks
Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts , July 23, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II). This collaboration strengthens Shire's rare disease pipeline of innovative therapies where there is high unmet need, and underscores the company's long standing commitment to the Hunter syndrome community.
Sign-up for Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen investment picks
Acquisition Strengthens Company's Focus on Communications Infrastructure ALISO VIEJO, Calif.
Sign-up for Microsemi Acquires Mingoa investment picks
SAN JOSE, Calif.
Sign-up for Andalay Solar Systems Launches the Sale of American Made Modules investment picks
New York Community Bancorp, Inc. (NYSE:NYCB) (the “Company”) today reported GAAP earnings of $118.7 million, or $0.27 per diluted share, for the three months ended June 30, 2014 and $233.9 million, or $0.53 per diluted share, for the six months ended at that date.
Sign-up for New York Community Bancorp, Inc. Reports 2Q 2014 Diluted Non-GAAP Cash Earnings Per Share of $0.29 (1) and Diluted GAAP Earnings Per Share of $0.27 investment picks
BOSTON, July 23, 2014 (GLOBE NEWSWIRE) -- NewStar Financial, Inc. (Nasdaq:NEWS) announced today that it will report results for the second quarter of 2014 on Wednesday, August 6, 2014 before the markets open.
Sign-up for NewStar Financial Schedules Release of Results for the Second Quarter of 2014 investment picks
The Dow Chemical Company (NYSE: DOW): Second Quarter 2014 Highlights The Company reported earnings of $0.73 per share, or $0.74 per share on an adjusted basis (1) .
Sign-up for Dow Reports Second Quarter Results investment picks
2014/7/23
By Barbara Kollmeyer, MarketWatch MADRID (MarketWatch) -- Wall Street stocks were set to open modestly higher on Wednesday, though earnings from Boeing Co.
Sign-up for UPDATE: U.S. stocks: Futures higher; Boeing ahead investment picks
2014/7/23
By Sara Sjolin, MarketWatch Looking for a new place to get attractive returns, low risk and high liquidity?
Sign-up for UPDATE: 5 things to know about the Saudi Arabia stock market investment picks
2014/7/23
Donate professional clothing until July 31 at Men's Wearhouse stores nationwide FREMONT, Calif.
Sign-up for Help Men Suit Up in the Final Week of The National Suit Drive investment picks
CHICAGO, July 23, 2014 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (Nasdaq:IPDN) ("PDN") announced today that Ms.
Sign-up for Professional Diversity Network Announces Donna Brazile Will be Joining Its Board of Directors investment picks
BETHESDA, Maryland and ABINGDON, Oxfordshire, July 23, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) , a global biopharmaceutical company, today announced that the United Kingdom's National Institute of Health and Care Excellence (NICE) has published the technology appraisal guidance recommending the use of AMITIZA ® (lubiprostone) in the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults who have failed laxatives.
Sign-up for Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone) investment picks
Biogen Idec Inc. (NASDAQ: BIIB) today reported second quarter 2014 results, including revenue of $2.4 billion, a 40% increase compared to the second quarter of 2013.
Sign-up for Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year investment picks
Piling Contractors Can Now Realize Increased Productivity with Trimble 3D Machine Control SUNNYVALE, Calif.
Sign-up for Trimble Announces Land-based 3D Piling Application for Mixed Fleets investment picks
SITECH Intermountain Joins the First Fully Dedicated Global Distribution Network for Construction Technology Solutions SUNNYVALE, Calif.
Sign-up for SITECH Technology Dealer Established in the Intermountain Region to Serve Heavy Civil Construction Contractors investment picks
Integrated Device Technology, Inc. ( IDT ® ) (NASDAQ:IDTI) today announced the expansion of its leading PCIe timing portfolio with the industry’s first 1.5 V PCI Express (PCIe ® ) buffer family .
Sign-up for IDT Announces 1.5 Volt PCI Express® Clock Buffer Family Offering Industry-leading Space and Power Savings investment picks
SPOKANE, Wash., July 23, 2014 (GLOBE NEWSWIRE) -- Potlatch Corporation (Nasdaq:PCH) today reported net income of $16.3 million, or $0.40 per diluted share, on revenues of $143.9 million for the quarter ended June 30, 2014.
Sign-up for Potlatch Reports Second Quarter 2014 Results investment picks
2014/7/23
Rapidly expanding trend toward interconnectivity of everyday devices could yield $1.9 trillion in global economic value-add by 2020.
Sign-up for Executive Talent Needs From Rising 'Internet of Things' Trend Spurs Heidrick & Struggles to Launch New Specialty Practice investment picks
2014/7/23
Second Quarter Financial Highlights * *All comparisons versus second quarter 2013.
Sign-up for MarketAxess Reports Second Quarter 2014 Record Revenues of $65.0 Million, Pre-Tax Income of $29.1 Million and Diluted EPS of $0.48 investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia to MarketAxess Reports Second Quarter 2014 Record Revenues of $65.0 Million, Pre-Tax Income of $29.1 Million and Diluted EPS of $0.48
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices